TRIM proteins in cancer

Advances in Experimental Medicine and Biology

Volumn 770, Issue , 2012, Pages 77-91

  Cambiaghi, Valeria ^a   Giuliani, Virginia ^a   Lombardi, Sara ^a   Marinelli, Cristiano ^a   Toffalorio, Francesca ^a   Pelicci, Pier Giuseppe ^a,b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOSOME PROTEIN; ESTROGEN RESPONSIVE FINGER PROTEIN; ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN P53; REGULATOR PROTEIN; REPRESSOR PROTEIN; RET FINGER PROTEIN; RETINOIC ACID RECEPTOR ALPHA; SIRTUIN 1; TRANSCRIPTION FACTOR; TRANSCRIPTION INTERMEDIARY FACTOR 1 ALPHA; TRANSCRIPTION INTERMEDIARY FACTOR 1 GAMMA; TRIPARTITE MOTIF PROTEIN; TRIPARTITE MOTIF PROTEIN 13; TRIPARTITE MOTIF PROTEIN 22; TRIPARTITE MOTIF PROTEIN 28; TRIPARTITE MOTIF PROTEIN 29; TRIPARTITE MOTIF PROTEIN 32; TRIPARTITE MOTIF PROTEIN 8; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; TUMOR PROTEIN;

ARTICLE; CANCER GROWTH; CARCINOGENESIS; CHROMOSOME TRANSLOCATION; DISEASE ASSOCIATION; GENE LOCUS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; CHEMISTRY; GENE TRANSLOCATION; GENETICS; METABOLISM; NEOPLASM; REVIEW; SIGNAL TRANSDUCTION;

HUMANS; NEOPLASM PROTEINS; NEOPLASMS; SIGNAL TRANSDUCTION; TRANSLOCATION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

MLCS; MLOWN;

EID: 84878904155     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-5398-7_6     Document Type: Article

References (100)

1. I. Goddard AD, Borrow J, Freemont PS, et al. Characterization of a zinc finger gene disrupted by the t(l 5;17) in acute promyeloc ytic leuke mia. Science 1991; 254:B 71-4.
2. de The II, Lavau C, Marchio A, et al. The PML-RAR alpha fusion mRNA generated by the t(l 5;17) translocat ion in acute promyelocytic leukemia encode s a functiona lly altered RAR. Cell 1991; 66:675-84.
3. Zhong S, Delva L, Rachez C, et al. A RA-dependent, tumour-growth suppressive transcription complex is the targe t of the PML-RARalpha and Tl 8 oncoproteins. Nat Genet 1999; 23:287-95.
4. Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999; 93:3 167-215 .
5. Grignani F, De Matteis S, Nerv i C, et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 1998; 391:815-8 .
6. TsimberidouAM,Tirado-Gomez M,Andreeff'M, et al. ;AndersonCancerCenterSeries. Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemi a: an update of The University of Texas M. D. Anderson Cancer Center Series . Leuk Lymphoma 2006; 47: 1062-8 .
7. Zhang XW, Yan XJ, Zhou ZR, et al. Arsenic trioxide controls the fate of the pML-RARalpha oncoprotein by directly binding pML. Science 2010; 328:240-3.
8. Lallem and-Breitenbach Y, Zhu J, Chen Z, et al. Curing ApL through pML/RARA degrad ation by As203. Trends Mol Med 2012 ; 18:36-42.
9. Pandol fi PI'. In vivo analys is of the molecul ar genetics of acute promyelocytic leukemia. Oncogene 2001 ; 20:572 6-35.
10. Reymond A, Meroni G, Fantozzi A, et al. The tripartite motif family ident ifies cell compartments. EMBO J 200 I; 20:2140-51
11. Borden KL, Boddy MN, Lally J, et al. The solution structure of the RING finger domain from the acute promyclocytic leukaemia proto-oncoprot ein PML. EMBO J 1995; 14:1532-41.
12. Fagio liM,Alcalay M, Tomasson i Let al. Cooperation between the RING +BI-B2 and coiled-coil domains of Plvll. is necessary for its effects on cell survival. Oncogene 1998; 16:2905-13.
13. Fagio li M, Alcalay M, Pandolfi PI', et al. Alternativ e splicing of' Plvll. transcripts predicts coexpression of several carboxy-terminally different protein isoforms. Oncogene 1992; 7: I083-91.
14. Jensen K, Shiels C, Freemont PS. pML protein isoforms and the RBCC/TRIM motif. Oncogene 2001; 20:7223-33.
15. Koken MH, Puvion-Dutilleul F, Guillemin MC, et al. The t(15;17) translocation alters a nuclear body in a rctinoic acid-reversib le fashion. EMBO J 1994; 13:1073-83.
16. Weis K, Rambaud S, Lavau C, et al. Retinoic acid regulates aberrant nuclear localization of pML-RAR alpha in acute promyelocytic leukemia cells. Cell 1994; 76:345-56.
17. Dyck JA, Maul GG, Miller WH Jr., et al. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 1994; 76:333-43.
18. IshovAM, SotnikovAG,Negorev 0, et al. pML is critical forNOl Oformation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-I. J Cell Bioi 1999; 147:221-34.
19. Zhong S, Hu L, Ye TZ, et al. A role for pML and the nuclear body in genomic stability. Oncogene 1999; 18:794 1-7.
20. Lin HK, Bergmann S, Pandol fi PI'. Cytoplasmic pML function in TGF-beta signalling . Nature 2004; 431:205-11.
21. Giorgi C, Ito K, Lin HK, et al. pML regulates apoptosis at endoplasmic reticulum by modulating calcium release. Science 2010; 330:1247-51.
22. Yeager TR, Neumann AA, Englezou A, et al. Telomerase-negativ e immortalized human cells contain a novel type of promyelocytic leukemia (pML) body. Cancer Res 1999; 59:4175-9.
23. Wang ZG, Delva L, Gaboli M, et al. Role of pML in cell growth and the retinoic acid pathway. Science 1998; 279:1547-51.
24. Mu ZM, Chin KY, Liu JH, et al. pML, a growth suppressor disrupted in acute promyelocytic leukemia. Mol Cell BioI 1994; 14:6858-67.
25. Wang ZG, Ruggero 0, Ronchetti S, et al. pML is essential for multiple apopto tic pathways. Nat Genet 1998; 20:26 6-72.
26. GuoA, SalomoniL, LuoJ, et al.The function of'Plvll. in p53-dependent apoptosis. NatCell Bio12000;2:730-6 .
27. Yang S, Kuo C, Bisi JE, Kim MK. PML-dependent apoptosis after DNA damage is reg ulated by the checkpoint kinase hCds I/Chk2. Nat Cell BioI 2002; 4:865-70
28. Hofm ann TG, Moll er A, Sirm a H, et al. Regul ati on of p53 activ ity by its int eracti on wit h homeodomain-interacting protein kinase-2. Nat Cell BioI 2002; 4:1-10 .
29. D'Orazi G, Cecch inelli B, Bruno T, et al. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell BioI 2002; 4:11-9.
30. Oda K, Arakawa H, Tanaka T, et al. p53AIpI, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated L53. Cell 2000 ; 102:849-62
31. Lain S, Midgley C, Sparks A, et al. An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and L53 to UIA -positive nuclear bodies associated with the PODs. Exp Cell Res 1999; 248:45 7-72.
32. Wei X, Yu ZK, Ramalingam A, et al. Physical and functional interactions between pML and MDM2. J BioI Chern 2003; 278:29288-97.
33. Louria -Hayon I, Grossman T, Sionov RY, et al. The promyelocytic leukem ia protein protect s L53 from Mdm2-mediated inhibiti on and degradation. J BioI Chern 2003 ; 278:33 134-4 1.
34. Kurki S, Latonen L, Laiho M. Cellular stress and DNA damage invoke temporally distinct Mdm2, L53 and pML complexes and damage-specific nuclear relocalization. J Cell Sci 2003; 116:3917-25.
35. Berna rdi R, Pandolfi PP. Role ofPML and the PML-nuclear body in the contro l of programmed cell death. Oncoge ne 2003; 22:9048-57.
36. Carracedo A, Ito K, Pandolfi PP. The nuclear bodies inside out: PML conq uers the cytoplas m. Curr Opin Cell BioI 20 11; 23:360 -6.
37. Pearso n M, Carbone R, Sebastian iC, et al. PML regulates p53 acety lation and premature senesce nce induced by oncogenic Ras. Nature 2000; 406:207-10.
38. Langley E, Pearson M, Farctta M, et al. Human SIR2 deacetylates p53 and antago nizes PML/p53 -ind uced cellular senes cence. EMBO J 2002; 21:2383-96.
39. Le Douarin B, Pierrat B, vom Baur E, et al. A new version of the two-hybrid assay for detection of protein-protein interactions. Nucleic Acids Res 1995; 23:876-8
40. Gandini D, De Ange liC, Aguiari G, et al. Preferential express ion oft he transcription coactiva tor HTIF Ialpha gene in acute myelo id leukemia and MDS-related AML. Leukemia 2002; 16:886-93
41. Khetchoumian K, Tele tin M, Tisserand J, et al. Loss ofTrim24 (Tifl alpha) gene function confers oncogenic activity to retinoic acid receptor alpha. Nat Genet 2007; 39:1500-6.
42. Aasla nd R, Gibson TJ, Stewart AF. The PHD finger: implications for chromatin-mediated transcriptional regulation. Trends Biochem Sci 1995; 20:56-9.
43. Koken MH, Sarb A, de The H. A C4HC3 zinc finger motif. C R Acad Sci III 1995; 318 :733-9
44. Jea nmougin F, Wurtz JM, Le Douarin B, et al. The bromodomain revisit ed. Trends Biochem Sci 1997; 22:151-3.
45. Le Douarin B, vom Baur E, Zechel C, et al. Ligand-dependent interaction ofnuclear receptors with potential transcripti onal interme diary factors (mediators). Philos Tra ns R Soc Lond B Bioi Sci 1996; 351 :569-78 .
46. Meroni G, Diez-Roux G. TRIM/RBCC, a novel class of csingle protein RING finger ' E3 ubiquitin ligases. Bioessays 2005; 27:1147-57.
47. Tsai WW, Wang Z, Yiu TT, et al. TRIM24 links a non-canonical histone signature to breast cancer. Nature 2010; 468 :927-32.
48. Tisserand J, Khetchoumian K, Thibault C, et al. Tripartite motif 24 (Trim2 4/Tifla) tumor suppressor protein is a nove l nega tive regulator of interferon (lFN)/signal transducers and activa tors oftranscription (STA T) signaling pathway acting through retinoic acid receptor a (Ram) inhibitio n. J BioI Chern 20 11; 286:33369-79 .
49. Miki T, Fleming TP, Crescenzi Met al. Development ofa highly efficient expression cDNA cloning system : application to oncogene isolation. Proc Nat! Acad Sci USA 1991; 88:5 167-71.
50. Klugbauer S, Rabes HM. The transcription coactivator HTIFI and a related protein are fused to the RET receptor tyrosine kinase in childhood papillary thyroid carcinomas . Oncoge ne 1999; 18:4388 -93.
51. Venturini L, You J, Stadler M, et al. TlFlgamma, a novel member ofthe transcriptional interme diary factor I family. Oncogene 1999; 18:1209-17.
52. He W, Dorn DC, Erdjument-Bro mage Het al. Hematopoiesis controlled by distinct TlFlgammaand Smad4 branches of the TGFbeta pathway. Cell 2006; 125:929-41.
53. Aucag ne R, Droin N, Paggetti J, et al. Transcription interm ediary factor Iy is a tumor suppressor in mouse and human chro nic myelomonocyti c leukemia. J Clin Invest 2011 ; 12 1:236 1-70.
54. Henry J, Ribo uchon MT, Offer C, et al. B30.2-like domain proteins: a growi ng family . Biochem Biophys Res Commun 1997; 235:162-5.
55. Takahashi M, Inaguma Y, Hiai Hetal. Develop mentally regulatede xpressionofah uman " finger"-c ontaining gene encoded by the 5' half ofthe ret transforming gene. Mol Cell BioI 1988; 8: 1853-6.
56. TakahashiM, RitzJ, CooperGM. Activationofanovelhuman transfo rming gene, ret, by DNA rearrangement. Ce ll 1985; 42:58 1-8.
57. Taka hashi M, Coop er GM. ret transforming gene encodes a fusion protein homologo us to tyrosine kinases. Mol Cell BioI 1987; 7: 1378-85.
58. Cao T, Duprez E, Borden KL, et al. Ret finger protein is a normal component of PML nucle ar bodies and interacts directly with PML. J Cell Sci 1998; I I I: 1319-29 .
59. Shimono Y, Murakami H, Hasegawa Y, et al. RET finger protein is a transcriptional repressor and intera cts with enha ncer of polycomb that has dual transcriptional functions. J BioI Chern 2000; 275 :3941 1-9.
60. Shimono Y, Murakami H, Kawai K, et al. Mi-2 beta associates with BRG I and RET finger protein at the distinct reg ions with transcriptional activa ting and repress ing abilities . J BioI Chern 2003; 278 :51638-45 .
61. Bloor AJ, Kotso poulou E, Hayward P, et al. RFP represses trans criptional activation by bHLH transc riptio n factors. Oncogene 2005; 24:6729 -36.
62. Fukushige S, Kondo E,GuZ, et al. RET finger protein enhancesMBD2-andMBD4- dependent transcriptio nal repression. Biochem Biophys Res Commun 2006; 35 1:85-92.
63. Krutzfeldt M, Ellis M, Weekes DB, et al. Selective ablatio n of retino blastoma protein function by the RET finger protein. Mol Ce ll 2005 ; 18:2 13-24.
64. Miyak e S, Sellers WR, Safran M, et al. Cells degrade a novel inhibitor of differentiation with EIA-like propert ies upon exiting the cell cycle . Mol Ce ll Bioi 2000 ; 20:8889-902.
65. Tezel GG, Uner A, Yildiz I, et al. RET finger protein expression in invasive breast carc inoma: relationship betwee n RFP and ErbB2 expression. Pathol Res Pract 2009; 205:403-8.
66. Chu Y, Yang X. SUMO E3 ligase activity ofTRIM proteins. Oncogene 2011; 30:1108-16.
67. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance . Nat Rev Cancer 2002; 2:101-12.
68. Tamoxifen for early breast cancer : an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Grou p. Lancet 1998; 351:1451-67.
69. Ikeda K, Orimo A, Higashi Y, et al. Efp as a primary estrogen-responsive gene in human breast cance r. FEBS Lett 2000; 472:9-13.
70. Urano T, Saito T, Tsukui T, et al. Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth . Nature 2002; 41 7:871-5.
71. Suzuki T, Urano T, Tsukui T, et al. Estrogen-responsive finger protein as a new potentia l biomarker for breast cancer. Clin Cancer Res 2005; 11:6148-54.
72. Nakaj ima A, Maruyama S, Bohgaki Met al. Ligand-depende nt transcription of estroge n receptor alpha is mediated by the ubiquitin ligase EFP. Biochem Biophys Res Commun 2007; 357:245-51.
73. Ueyama K, Ikeda K, Sato W, et al. Knockdown ofEfp by DNA-modified small interfering RNA inhibits breast cancer cell proliferation and in vivo tumor growth . Cancer Gene Ther 20 10; 17:624-32.
74. Frank DJ, Roth MB. ncl-I is required for the regulation of cell size and ribosomal RNA synthes is in Caenorhabditis elegans. J Cell BioI 1998; 140:1321-9.
75. Fridell RA, Harding LS, Bogerd HPe t al. Identification ofanovel human zinc finger protein that specifically interacts with the activa tion domain of lentiviral Tat proteins. Virology 1995; 209:347-57.
76. Slac k FJ, Ruvkun G. A novel repea t domain that is often associated with RING finger and B-box motifs. Trends Biochem Sci 1998; 23:4 74-5.
77. Hom EJ, Albor A, Liu Y, et al. RING protein Trim32 assoc iated with skin carcinogenesis has anti-apoptotic and E3-ubiquitin ligase properties. Carcinogenesis 2004; 25:157-67.
78. Frosk P, Weiler T, Nylen E, et al. Limb-girdle musc ular dystrophy type 2H assoc iated with mutation in TRIM32, a putative E3-ubiquitin-ligase gene. Am J Hum Genet 2002; 70:663-72.
79. Chiang AP, Beck JS, Yen HJ, et al. Homozygosity mapping with SNP arrays identifies TRIM32, an E3 ubiquitin ligase, as a Bardet-Biedl syndrome gene (BBS 11). Proc Natl Acad Sci USA 2006; 103:6287-92.
80. Kudryashova E, Wu J, Havton LA, et al. Deficiency of the E3 ubiquitin ligase TRIM32 in mice leads to a myopathy with a neurogenic component. Hum Mol Genet 2009; 18:1353-67
81. Kulesz-Mart in MF, Penetrante R, East CJ. Benign and malignant tumor stages in a mouse keratinocyte line treated with 7,12-dimethylbenz[a]anthracene in vitro . Carcinogenesis 1988; 9:171-4.
82. Albor A, EI-Hizawi S, Horn EJ, et al. The interac tion of Piasy with Trim32, an E3-ubiquitin ligase mutated in limb-girdl e muscular dystro phy type 2H, promotes Piasy degradation and regulates UVB-induced keratinocyte apoptosis through NFkappaB. J Bioi Chern 2006; 281:25850-66.
83. Ryu YS, Lee Y, Lee KW, et al. TRIM32 protein sensitizes cells to tumor necrosis factor (TNFa)-induced apoptosis via its RING domain-depe ndent E3 ligase activ ity against X-linked inhibitor of apoptosis (XIAP). J BioI Chern 2011; 286:25729-38.
84. Sato T, Okumura F, Kano S, et al. TRIM32 promotes neural differentiation through retinoic acid receptor-mediated transcription. J Cell Sci 2011; 124:3492-502.
85. Vincent SR, Kwasnicka DA, Frctier P. A novel RING finger-B box-coiled-coil protein, GERP. Biochem Biophys Res Comm un 2000; 279:482-6.
86. Car inci F, Arce lli D, Lo Muzio L, et al. Molecular classification of noda l metastas is in primary larynx squa mous cell carcinoma. Transl Res 2007; 150:233-45.
87. Tonia to E, Chen XP, Losman J, et al. TRIM8/GERP RING finger protein interacts with SOCS-1. J Biol Chern 2002; 277:37315-22.
88. Okumura F, Matsunaga Y, Katayama Yet al. TRIM8 modulates STAT3 activity through negative regulation ofPIAS3. J Cell Sci 2010; 123:2238-45.
89. Okumura F, Okumura AJ, Matsumoto M, et al. TRIM8 regulates Nanog via IIsp9013-mediated nuclear translocatio n ofSTAT3 in embryo nic stem cells. Bioch im Biophys Acta 2011; 1813:1784-92.
90. Caratozzolo MF, Micale L, Turturo MG, et al. TRIM8 modulates p53 activity to dictate cell cycle arrest. Cell Cycle 20 12; 11:511-23
91. Allton K, Jain AK, Herz M, et al. Trim24 targets endogeno us p53 for degradation. Proc Natl Acad Sci USA 2009; 106:11612-6.
92. Jain AK, Barton MC. Regulation of p53: TRIM24 enters the RING. Cell Cycle 2009; 8:3668-74.
93. Alsheich-Bartok 0, Haupt S, Alkalay-Snir l, et al. PML enhances the regulatio n of p53 by CK I in respo nse to DNA damage. Oncogene 2008; 27:3653-6 1.
94. Wang C, Ivanov A, Chen L, et al. MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactiva tion. EMBO J 2005; 24:3279-90.
95. Yang B, O'Herrin SM, Wu Jet al. MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAr l and suppress p53-d ependent apoptosis inMAGE-posit ive ccll iines.Cancer Res 2007; 67:9954-62.
96. Yuan Z, Villagra A, Peng L, et al. The ATOC (TRIM29) protein binds p53 and antagonizes p53-mediated functions. Mol Cell Bioi 2010; 30:3004-15.
97. Yuan Z, Peng L, Radhakrish nan R, et al. Histone deacetylase 9 (HOAC9) regulates the functio ns of the ATOC (TRIM29) protein. J Bioi Chem 2010; 285:39329-38.
98. Sho T, Tsukiyama T, Sato T, et al. TRIM29 negatively regulates p53 via inhibition of Tip60. Biochim Biophys Acta 201 I; 1813:1245-53.
99. Joo HM, Kim JY, Jeong JB, et al. Ret finger protein 2 enhances ionizing radiation-i nduced apoptosis via degradation ofAKT and MOM2. Eur J Cell Bioi 20 I I ; 90:420-3 1.
100. Obad S, Brunnstrom H, Vallon-Christersso n J, et al. Staf50 is a novel p53 target gene conferring reduced c1onogenic growth ofIeukemic U-937 cells . Oncogene 2004; 23:4050-9.